Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne…
Dyne Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DYNE-251 for the treatment of Duchenne muscular dystrophy (DMD)…
Read More...
Read More...
